Vanhaesebroeck, Bart;
Burke, John E;
Madsen, Ralitsa R;
(2022)
Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation.
Cancer Discovery
, 12
(1)
pp. 20-22.
10.1158/2159-8290.CD-21-1411.
Preview |
Text
Vanhaesebroeck_Cancer Discovery_mutant PI3Ka degraders_Nov 15_QC.pdf Download (324kB) | Preview |
Abstract
PIK3CA, which encodes the p110α catalytic subunit of PI3Kα, is one of the most frequently genetically activated kinases in solid tumors. In this issue of Cancer Discovery, Song and colleagues report that the related PI3Kα inhibitors taselisib and inavolisib trigger receptor tyrosine kinase (RTK)-dependent degradation of the mutant p110α protein in breast cancer cells that are positive for HER2 RTK, limiting feedback-mediated drug resistance and potentially widening the therapeutic index of PI3Kα inhibition.See related article by Song et al., p. 204.
| Type: | Article |
|---|---|
| Title: | Precision Targeting of Mutant PI3Kα in Cancer by Selective Degradation |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1158/2159-8290.CD-21-1411 |
| Publisher version: | https://doi.org/10.1158/2159-8290.CD-21-1411 |
| Language: | English |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Oncology |
| UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10143833 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
